^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

letaplimab (IBI188)

i
Other names: IBI188, IBI 188, IBI-188
Associations
Company:
Innovent Biologics
Drug class:
CD47 inhibitor
Associations
1year
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
P1/2, N=222, Suspended, Innovent Biologics (Suzhou) Co. Ltd. | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
Trial completion date • Trial primary completion date • Combination therapy
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
azacitidine • decitabine • letaplimab (IBI188)
almost2years
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
P1/2, N=222, Suspended, Innovent Biologics (Suzhou) Co. Ltd. | N=126 --> 222 | Trial completion date: May 2022 --> Jun 2024 | Recruiting --> Suspended | Trial primary completion date: Apr 2021 --> Jun 2023
Enrollment change • Trial completion date • Trial suspension • Trial primary completion date • Combination therapy
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
azacitidine • decitabine • letaplimab (IBI188)
3years
Suppression of Extracellular Vesicle CD47 Induces Systemic Anti-DLBCL Immunity (ASH 2021)
Anti-CD47 antibody (IBI188) has shown promise in treating tumors, including Diffuse large B cell lymphoma (DLBCL)...Moreover, high levels of circulating EV CD47 would follow and correlate positively with the phagocytic activity of macrophages, and reflect the presence of a successful anti-tumor immunity elicited by the anti-CD47 therapy. Together, these findings show that EV CD47 represents an unexplored therapeutic target, which could overcome resistance to current CD47 antibody approaches.
IO biomarker
|
CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
letaplimab (IBI188)